Third Rock Ventures Reduces Stake in Tango Therapeutics Below 5% Threshold

summarizeSummary

Third Rock Ventures, a significant institutional investor, has reduced its ownership in Tango Therapeutics to 4.74% through open market sales totaling approximately $18.84 million, crossing the 5% reporting threshold.

check_boxKey Events

• Significant Stake Reduction

  Third Rock Ventures decreased its ownership from above 5% to 4.74% of Tango Therapeutics' common stock.

• Substantial Open Market Sales

  The reduction was executed through multiple open market dispositions between January 21, 2026, and February 6, 2026, totaling approximately 1.5 million shares for about $18.84 million.

• Below Reporting Threshold

  The institutional investor's stake has now fallen below the 5% threshold, which typically reduces future detailed reporting obligations.

auto_awesomeAnalysis

This Schedule 13D/A filing indicates that Third Rock Ventures, a major institutional investor, has significantly reduced its stake in Tango Therapeutics. The sales, totaling approximately $18.84 million, represent a substantial capital outflow and have brought their ownership below the 5% threshold, which typically triggers a change in reporting requirements. While institutional investors often rebalance portfolios, a reduction of this magnitude by a long-term holder can be interpreted as a decrease in conviction or a strategic reallocation of capital. Investors should monitor future filings for further changes in institutional ownership.